JERSEY CITY, N.J. , Aug. 9, 2022 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of market assessment report on "Global Peptide–drug Conjugates (PDCs) Market By Product (Lutetium Lu 177 dotatate, Melflufen, ANG1005, BT1718, CBX-12, and Other Pipeline Products) By Indication (Relapsed/Refractory Multiple Myeloma, Neuroendocrine Tumors (NETs), Gastric Cancers, Acromegaly, Ophthalmology, and Other Cancer Indications. )– Technology Trends, Industry Competition Analysis, Revenue and Forecast Till 2030"
According to the latest research by InsightAce Analytic, the global peptide–drug conjugates (PDCs) market is expected to record a promising CAGR of 13.7% during the period of 2022-2030. By region, North America dominates the global peptide–drug conjugates (PDCs) market with the largest share.
Request for Sample Pages: https://www.insightaceanalytic.com/report/global-peptidedrug-conjugates-pdcs-market/1351
The peptide drug conjugates are targeted therapeutic drugs, targeting the tumor cell to release the cytotoxin. The swelling investments by key players to develop promising therapies are anticipated to fuel the market growth over the forecast period. The emergence of Peptide–Drug Conjugates (PDCs) therapy for patients suffering from different types of cancers is believed to create a number of clinical opportunities during the forecast period. PDC uses a peptide chain of about ten amino acids to target tumour cells, and its molecular weight is smaller than ADC, which can be rapidly enriched to tumour sites. At the same time, drug molecules in blood can be cleared quickly with a short half-life, helping to reduce toxic side effects caused by off-targeting.
Peptide–drug conjugates (PDCs) are a novel targeted therapy that exhibits enhanced tumour penetrance and selectivity. Peptide–drug conjugates (PDCs) are a promising field of study, as evidenced by the two PDCs now available on the market. In addition, PDCs with the proper design and focus is expected to affect the targeted therapeutic market by delivering safer medications. The increasing number of pharmaceutical drug innovations is expected to fuel the growth of peptide–drug conjugates (PDCs) market in the near future. Also, in the coming days, there will be rapid approval of peptide drug conjugates in treating cancers due to the robust clinical pipeline of drugs. Despite these, the peptide drug conjugates have several limitations which hinder the growth of the PDCs market. Major driving factors of peptide–drug conjugates (PDCs) market are the increasing need for therapeutic drugs, high prevalence of cancer diseases, rising number of clinical trials, and increasing investments by key players to develop promising therapies. Furthermore, advanced medical technologies, growth in the population, and a growing number of health-conscious people enhance the market growth.
However, the high-cost treatments, complex procedures, and lack of strict government laws limit the market growth. Moreover, the COVID-19 pandemic has negatively impacted this market due to the lockdown situation. In addition, the pipeline product approval process may hamper the product market and production as a lot of clinical trials are going on today. On the other hand, FDA has approved very few pipeline products regarding peptide drug conjugates in the last five years, which will impact the market in the forecasting period.
At the regional level, North America , followed by the Europe region, is expected to hold the highest share of this market over the forecast period due to the high prevalence of cancer, fast adoption of advanced technologies, rising awareness about therapeutic drugs, and increasing government investments and funding in R&D of therapeutic medications. In addition, the Asia-Pacific region is expected to show significant market growth in the future owing to the advancement of modern technologies and the rising prevalence of cancer.
The key players involved in peptide–drug conjugates (PDCs) industry are Novartis AG, AstraZeneca, Bicycle Therapeutics, Cybrexa Therapeutics, Esperance Pharmaceuticals, Oncopeptides AB, Pepgen Corporation, Soricimed Biopharma, Theratechnologies, Pfizer Inc, Validus Pharmaceuticals LLC, Antisense Therapeutics, Midatech Pharma PLC, Ipsen Pharma, Chiasma, Inc., Peptron, Inc., CRINETICS PHARMACEUTICALS, Dauntless Pharmaceuticals, Camurus AB, Teva Pharmaceuticals Inc., Pharmaspur, Aspire Pharmaceuticals, Ionis Pharmaceuticals Inc, Midatech Pharma Plc, and Other Prominent Players. This field's leading players use strategies like novel therapy innovations, partnerships, collaborations, mergers, and agreements.
Key developments in the market
In Dec 2021 , A strategic partnership agreement was signed between Coherent Biopharma and WuXi STA. In order to speed up the development of its current and future drug candidates (small molecules, peptides, oligonucleotides, complex chemical conjugates, etc.), from API to drug product, the company will offer Coherent Biopharma integrated CMC services.
In Oct 2021 , Oncopeptides AB announced the withdrawal of Pepaxto® (INN melphalan flufenamide) from the US market. Oncopeptides will collaborate with the FDA to keep the drug available for patients who are currently receiving Pepaxto treatment.
In July 2020 , AstraZeneca and Daiichi Sankyo formed a new $6 billion global ADC alliance to co-develop and commercialise DS-1062, a TROP2 directed DXd antibody-drug conjugate in Phase I for non-small cell lung cancer and breast cancer. The businesses will share development and commercialization costs as well as profits from DS-1062 worldwide, except for Japan .
In June 2019 , Novartis AG and PeptiDream Inc. signed a new Peptide Drug Conjugate "PDC" collaboration agreement to initiate macrocyclic peptide discovery, which will be used to address therapeutic and diagnostic applications.
Curious about Details @ https://www.insightaceanalytic.com/report/global-peptidedrug-conjugates-pdcs-market/1351
Global peptide–drug Conjugates (PDCs) Market, by Product, 2022-2030 (Value US$ Mn)
Global peptide–drug Conjugates (PDCs) Market, by Indication, 2022-2030 (Value US$ Mn)
Global peptide–drug Conjugates (PDCs) Market, by Region, 2022-2030 (Value US$ Mn)
North America Peptide–drug Conjugates (PDCs) Market, by Country, 2022-2030 (Value US$ Mn)
Europe Peptide–drug Conjugates (PDCs) Market, by Country, 2022-2030 (Value US$ Mn)
Asia Pacific Peptide–drug Conjugates (PDCs) Market, by Country, 2022-2030 (Value US$ Mn)
Latin America Peptide–drug Conjugates (PDCs) Market, by Country, 2022-2030 (Value US$ Mn)
Middle East & Africa Peptide–drug Conjugates (PDCs) Market, by Country, 2022-2030 (Value US$ Mn)
Rest of Middle East & Africa
For More Customization @ https://www.insightaceanalytic.com/customisation/1351
Why should buy this report:
To receive a comprehensive analysis of the prospects for global peptide–drug conjugates (PDCs) products
To receive industry overview and future clinical trial/pipeline trends of global peptide–drug conjugates (PDCs) market
To analyse the peptide–drug conjugates (PDCs) market drivers and challenges
To get information on peptide–drug conjugates (PDCs) market size value (US$ Mn) forecast till 2030
To get information on major Investments, Mergers & Acquisition in global peptide–drug conjugates (PDCs) market industry
Other Related Reports Published by InsightAce Analytic:
Global Polymer Drug Conjugates Market
Global Neoantigen Peptides Manufacturing Market
Global Antibody Drug Conjugates (Adcs) – Linker And Conjugation Technologies Market
Global Peptide CDMO (Pharmaceutical) Market
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact Us: InsightAce Analytic Pvt. Ltd. Tel.: +1 551 226 6109 Email: info@insightaceanalytic.com Site Visit: www.insightaceanalytic.com Follow Us on LinkedIn @ bit.ly/2tBXsgS Follow Us On Facebook @ bit.ly/2H9jnDZ
Logo: https://mma.prnewswire.com/media/1729637/InsightAce_Analytic_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/peptidedrug-conjugates-pdcs-market-future-pipelineclinical-trial-analysis-and-revenue-forecast-snapshot---exclusive-report-by-insightace-analytic-301602539.html
SOURCE InsightAce Analytic Pvt. Ltd.
New drugs from Eli Lilly and Novo Nordisk have shown striking results in studies. If insurers step up to back them, the drugs—and the stocks—could take off.
Strong crude oil prices have once again brought investors' attention to energy stocks that have long been underperforming. The West Texas Intermediate crude oil price has largely been above $90 per barrel since the beginning of March. Here are two stocks that have delivered solid dividend growth consistently over the years, irrespective of oil prices.
Vaxxinity missed out on Operation Warp Speed and the first round of COVID-19 vaccines, but CEO Mei Mei Hu is focused on the second generation and ongoing global needs.
Alibaba Group Holding Limited (NYSE: BABA) and Tencent Holding Ltd (OTC: TCEHY) submitted the algorithm details of some of their products to China's top internet watchdog, Reuters reports. The submission was a part of China's sweeping crackdown on the sector. The internet platforms faced flak for abusing algorithms to invade user privacy and manipulate their choices. The Cyberspace Administration of China (CAC) published a list of 30 algorithms used in some of the country's most popular apps, in
China's latest military exercises encircling Taiwan in response to U.S. House Speaker Nancy Pelosi’s visit to Taipei last week has clear ramifications for the global economy.
The pharma giant hit back at allegations that the use of Zantac, known chemically as ranitidine, increases the risk of cancer.
Analysts at Goldman Sachs said commodity markets were behaving irrationally, and warned of "unsustainable prices." Prices and inventories are falling, while demand is beating expectations and supply is disappointing, they said in a note late Thursday. Normally, a combination of higher demand and lower supply would make prices rise. The bank lowered its forecast for Brent prices earlier this week. It now predicts $125 a barrel in three months' time and $120 a barrel in 12 months. Goldman Sachs pr
Kazakhstan is expected to sell some of its crude oil through Azerbaijan's biggest oil pipeline from September, as the nation seeks alternatives to a route Russia threatened to shut, three sources familiar with the matter said. For 20 years, they have been shipped through the CPC pipeline to Russia's Black Sea port of Novorossiisk, which provides access to the global market. In July a Russian court threatened to shut the CPC, prompting the Kazakh government and major foreign producers to set up contracts for other outlets as a precaution.
The country is contending with its worst nuclear outages in decades, putting it at greater risk of blackouts this winter than big neighbors experiencing their own energy headaches.
The U.S. climate bill, along with a parallel initiative in Europe, could reshape global energy. Plug Power, Sunrun, and other companies could make the most of the new opportunities in renewables.
Pfizer (PFE) offers to buy Global Blood Therapeutics (GBT) for $5.4 billion in cash. J&J (JNJ) to discontinue selling talc-based baby powder globally from 2023.
Merck (NYSE: MRK) is best known for the top-selling cancer drug in the world, Keytruda, which has produced a staggering $10.1 billion in sales through the first half of this year. Keytruda comprised only 33% of the drugmaker's $30.5 billion in total first-half sales. Merck has a pipeline of more than 100 projects under clinical development, which should give it enough firepower to grow revenue and profits with new product launches.
Many people don't realize it, but knowing what time of day to take your medications makes a big difference with several prescriptions. When taking a new med, it's vital to ask your physician or pharmacists everything to know about the drug and what time of day will be most effective. Eat This, Not That! Health spoke with Nima Majlesi, DO, Director of Medical Toxicology at Staten Island University Hospital who shares five different medications to avoid taking in the morning and why. Please consul
(Bloomberg) -- The globe is in the grips of a climate crisis as temperatures soar and rivers run dry, and yet it’s never been a better time to make money by digging up coal.Most Read from BloombergAnshu Jain, Deutsche Bank Chief in a Pivotal Era, Dies at 59Author Salman Rushdie Stabbed on Lecture Stage in New YorkExtreme Heat Uncovers Lost Villages, Ancient Ruins and ShipwrecksTrump Search’s Revelations Open New Political Front for MidtermsTrump Calls for Release of Warrant Documents Used in Sea
Walking—with no bells and whistles, just simply putting one foot in front of the other—has been repeatedly linked to improving overall health, including increasing lifespan. Even walking for just 15 minutes four times a week has been linked to living longer. If you’re an avid walker and want to ...
Demand remains strong for automakers, with supply constraints preventing inventory buildup and supporting strong pricing.
Monkeypox, now making headlines because of a rapidly-spreading outbreak, was a disease many people had never heard of until recently—let alone been afraid of getting. The name brings to mind smallpox—a disease that was globally eradicated in 1980—but monkeypox is a different illness. "Smallpox was very contagious and spread more easily than monkeypox," the Cleveland Clinic explains. "Monkeypox symptoms are similar to, but milder than, smallpox symptoms."In fact, smallpox is actually the only hum
Friends up north and across Tampa Bay snickered when Brian Lafferty revealed where he’d bought a new home. His 30-year-old daughter in Boston called to express concern. Even his ex-wife asked him about it. “Without exception, every person I’ve told I bought a house in The Villages has asked the same thing,” Lafferty said. “‘Isn’t that the STD capital of the United States?’” The Villages, a ...
Proud Hertfordshire father-of-three Mark Ryan, 37, first felt something was amiss in January
Let's check out a few charts of crude oil prices to see if the rally is resuming. In this daily bar chart of the nearby crude oil futures contract, below, we can see that prices are trying to regain their strength and close back above the rising 200-day moving average line. The daily On-Balance-Volume (OBV) looks like it has been improving in August.